Modulation of lipid metabolism for protein production

Abstract

The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.

1 - 44 . (canceled) 
     
     
         45 . A method for producing a recombinant therapeutic polypeptide in a cell, the method comprising:
 (i) providing a eukaryotic cell comprising a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM) comprising Sterol Regulatory Element-Binding Transcription Factor 1 (SREBF1), or a functional fragment or isoform thereof; and a second exogenous nucleic acid encoding the recombinant therapeutic polypeptide, wherein the recombinant therapeutic polypeptide is selected from an antibody, an antibody fragment, a hormone, a blood clotting factor, a cytokine or a protein vaccine; and   (ii) culturing the cell under conditions where the first LMM and the recombinant therapeutic polypeptide are expressed,   thereby producing the recombinant therapeutic polypeptide.   
     
     
         46 . The method of  claim 45 , wherein the first LMM provides an increased yield or rate of production of the recombinant therapeutic polypeptide as compared to a cell not having the first LMM. 
     
     
         47 . The method of  claim 46 , wherein the yield or rate of production of the recombinant therapeutic polypeptide is increased by 100% or more, as compared to the level or quantity of polypeptide produced by a cell without the first LMM. 
     
     
         48 . The method of  claim 45 , wherein the first LMM provides an increased ratio of properly folded recombinant therapeutic polypeptide to misfolded or unfolded recombinant therapeutic polypeptide as compared to a cell not having the first LMM. 
     
     
         49 . The method of  claim 45 , wherein the first LMM comprises an amino acid sequence with at least 80% identity with the amino acid sequence of SREBF1 corresponding to SEQ ID NOs: 1 or 34, or a functional fragment thereof corresponding to SEQ ID NOs: 26, 27, or 36; or differs by 1 or more amino acid residues but no more than 50 amino acid residues from the amino acid sequence of SREBF1, corresponding to SEQ ID NOs: 1 or 34, or a functional fragment thereof corresponding to SEQ ID NOs: 26, 27, or 36. 
     
     
         50 . The method of  claim 45 , wherein the cell further comprises a third exogenous nucleic acid encoding a second LMM comprising stearoyl CoA desaturase-1 (SCD1) or a functional fragment or isoform thereof, and in step (ii) the cell is cultured under conditions where the second LMM is expressed. 
     
     
         51 . The method of  claim 50 , wherein the second LMM comprises an amino acid sequence with at least 80% identity with the amino acid sequence of SEQ ID NO: 3, or a functional fragment thereof; or differs by 1 or more amino acid residues but no more than 50 amino acid residues from the amino acid sequence of SEQ ID NO: 3, or a functional fragment thereof. 
     
     
         52 . The method of  claim 45 , wherein the nucleic acid encoding the first LMM is integrated into the chromosomal genome of the cell and the LMM is stably expressed. 
     
     
         53 . The method of  claim 45 , wherein the cell is a mammalian cell. 
     
     
         54 . The method of  claim 53 , wherein the cell is a CHO cell. 
     
     
         55 . The method of  claim 45 , further comprising separating the recombinant therapeutic polypeptide from at least one cellular or medium component. 
     
     
         56 . The method of  claim 45 , wherein the second exogenous nucleic acid encoding a recombinant therapeutic polypeptide has been introduced after introducing the first exogenous nucleic acid encoding the first LMM.